Wednesday’s agenda opens with a keynote by Ken Keller, Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc., who uses his passion for innovation and compassion for patients as guiding principles of his leadership.

Kintsugi is the Japanese craft of taking something old—broken pottery—and restoring it to a form even more beautiful than its original state. Ken Keller, President and CEO, Daiichi Sankyo’s US business, and Global Head of the company’s Oncology Business, sees this ancient art form as a metaphor for the transformational journey the field of ADCs is currently taking to create new standards of care in oncology. With ADC trials increasing 500% in the past decade and new ADCs entering clinics every year, M&A activity is to be expected. Ken Keller will discuss Daiichi Sankyo’s quick pivot to create a new global oncology organization, built for speed, with a global mindset approach to supply chain, decision-making, and structures while aligning across all business functions.

Speakers

Ken Keller

President, CEO, Global Head of Oncology Business, Daiichi Sankyo, Inc.

Ken Keller is the Chairman of the Board, President and Chief Executive Officer of Daiichi Sankyo, Inc. He is also the Head of the Global Oncology Business responsible for leading the overarching company strategy of ensuring innovative medicines are available to patients with cancer around the world.

For more, please find the original story source here.